More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from preclinical to clinical milestonesTAMPA and LONDON, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the appointment of Kameel D. Farag as its Interim Chief Financial Officer who ...